Article info
PDFLetter
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
- Correspondence to Professor Carlo Salvarani, Unit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy; carlo.salvarani{at}ausl.re.it
Citation
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
Publication history
- Received May 7, 2020
- Revised May 16, 2020
- Accepted May 17, 2020
- First published May 28, 2020.
Online issue publication
May 13, 2021
Article Versions
- Previous version (14 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage